| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | September 27, 2023 |
| Accession Number: | 0001104659-23-103922 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/26/2023 | Mkt Outperform → Mkt Perform | JMP Securities |
JMP Securities downgraded Spectrum Pharma from Mkt Outperform to Mkt Perform
Combination of Assertio's Omni-Channel Digital Sales Capabilities and ROLVEDON In-Person Commercial Team to Enhance Market Access and Growth Across All Products Transaction Expected to be Significantly Accretive to Assertio in 2024 LAKE FOREST, Ill., July 31, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it has closed the proposed acquisition of Spectrum Pharmaceuticals, Inc. ("Spectrum") (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology. Assertio intends to provide updated guidance for the combined business
Stockholders From Both Assertio and Spectrum Have Overwhelmingly Voted in Support of the Transaction Transaction Expected to be Significantly Accretive to Assertio in 2024 LAKE FOREST, Ill. and BOSTON, July 27, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that its stockholders and the stockholders of Spectrum Pharmaceuticals, Inc. ("Spectrum") (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology, have each approved the proposed definitive agreement pursuant to which Assertio will acquire Spectrum in an all-stock and
Recommendations from the Nation's Leading Independent Proxy Advisory Firms Recognize Value Creation Opportunity for Spectrum Stockholders and Strength of the Combined Company Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) ("Spectrum" or the "Company") announced today that the leading independent proxy advisory firms, Institutional Shareholder Services, Inc. ("ISS") and Glass Lewis & Co. ("Glass Lewis"), have each recommended that Spectrum stockholders vote "FOR" the proposal to adopt the Agreement and Plan of Merger ("Merger Agreement", and such proposal, the "Merger Proposal") at the upcoming special meeting of stockholders (the "Special Meeting") on July 27, 2023. Under the terms of the M
4 - SPECTRUM PHARMACEUTICALS INC (0000831547) (Issuer)
4 - SPECTRUM PHARMACEUTICALS INC (0000831547) (Issuer)
4 - SPECTRUM PHARMACEUTICALS INC (0000831547) (Issuer)
15-12G - SPECTRUM PHARMACEUTICALS INC (0000831547) (Filer)
EFFECT - SPECTRUM PHARMACEUTICALS INC (0000831547) (Filer)
EFFECT - SPECTRUM PHARMACEUTICALS INC (0000831547) (Filer)